Clinical Outcomes: Cardiac AI’s Ultimate Economic Moat

Any slick software feature in digital health can be copied by a big competitor in a few months. That’s the reality. What can’t be copied quickly is a portfolio of strong, peer-reviewed clinical evidence. For anyone investing in cardiovascular AI, from growth equity to VC, this is the most important thing to understand. The real economic moat for these AI-native platforms is built on validated, published outcomes, proof that the tech actually improves patient care and lowers costs for the health system.

The AI-Native Imperative: Clinical Outcomes as the Ultimate Moat

An “AI-native company” is one that built its entire product, data flow, and business around AI from day one. That’s a good start, but it only gets you so far without hard clinical validation. You can’t just ship code and see what sticks like in other software categories. Clinical AI has to clear a much higher bar, especially in a field like cardiology where a wrong call directly affects patient survival. Investors need to see that the AI works in the chaos of a real hospital with a diverse patient population, and that its impact can be measured and repeated. This means we have to back companies that are plowing money into generating and publishing their own peer-reviewed trials, the kind that meet the standards of the American College of Cardiology (ACC). Without that proof, even a company with FDA clearance can become a “zombie”, no widespread use, no reimbursement codes, and no viable exit.

Case Studies in Clinical Evidence: Cleerly and HeartFlow

Just look at Cleerly and HeartFlow. Both companies are perfect examples of how to use clinical evidence to build a defensible market position, creating huge barriers for any would-be competitor.

Cleerly: Precision in Plaque Characterization

Cleerly’s niche is using AI to quantify and characterize coronary plaque from CT scans. It’s not just about finding blockages. Their platform details the plaque’s structure and makeup, which is what you need to predict a future heart attack. Their whole strategy is built on publishing peer-reviewed studies about this plaque analysis. You see their studies in major cardiology journals showing how their AI gives a far more precise risk score than traditional methods, leading to changes in clinical decisions for over 57% of patients and cutting the need for additional invasive and non-invasive tests by 37%. Their analysis is so good it shows high agreement with invasive imaging like intravascular ultrasound. They’ve got FDA 510(k) clearance for tools like Cleerly ISCHEMIA and a Breakthrough Device Designation for their CAD Staging System. All this published evidence is their core sales pitch to doctors, hospitals, and payers, proving their AI leads to better preventative care. For an investor, Cleerly’s constant stream of peer-reviewed data is a massive “data moat”, a competitor would have to spend millions and wait years to generate a similar evidence portfolio, which is what solidifies Cleerly’s valuation. Example peer-reviewed study on Cleerly’s plaque characterization

HeartFlow: Proving Cost Reduction in FFR-CT

HeartFlow is another leader that built its business on hard evidence, specifically proving the cost-effectiveness and better patient outcomes of its fractional flow reserve CT (FFR-CT) tech. Their AI takes a standard CT scan and builds a 3D model of the arteries, simulating blood flow to spot significant blockages without having to put a catheter in the patient. They poured money into huge clinical trials to prove this works. Their PLATFORM study showed that FFR-CT cut the number of unnecessary diagnostic catheterizations by 83% and dropped healthcare costs by 33% in one year. And just recently, the FUSION trial (August 2026) showed a 44% drop in needless invasive procedures. They consistently publish these cost-saving numbers in top journals, a study with NHS England (FISH&CHIPS, December 2025) even found a £1,042 GBP ($1,394 USD) savings per patient over two years. This kind of evidence is exactly what convinces hospitals to adopt the tech and payers to cover it, which is how you build a defensible market. Their obsessive focus on getting CPT codes, backed by this mountain of data, proves they get how to actually make money in healthcare, landing them a Category I CPT code set for January 2026 and coverage from giants like Cigna and UnitedHealthcare. PLATFORM study results in major cardiology journal

A Framework for Evaluating Evidence Strength in Cardiac AI

So when you’re looking at one of these AI-native health companies, how do you judge the strength of its evidence? Here’s a quick mental model built on three pillars. 1. Level of Evidence (LoE):

• Tier 1: Randomized Controlled Trials (RCTs): This is the gold standard. A company with multiple, well-designed RCTs showing its AI is better than (or at least as good as) the current standard of care has the strongest possible case. The best evidence is found in trials published in top-tier journals like JAMA Cardiology or the Journal of the American College of Cardiology.
• Tier 2: Prospective Cohort Studies & Registries: Real-world evidence (RWE) from big patient registries or prospective studies is the next best thing. It shows how the AI performs in the wild and over the long term. Using data from a source like the American College of Cardiology registry is a great way to do this.
• Tier 3: Retrospective Studies & Expert Consensus: This is the weakest tier. It’s fine for generating ideas, but you can’t build a defensible market position on retrospective data or a panel of opinions. 2. Clinical Impact & Outcomes:
• Hard Clinical Endpoints: The AI should show a measurable drop in major adverse cardiac events (MACE), better survival rates, or fewer hospitalizations. These are the outcomes that really move the needle because they directly map to saving lives and serious money.
• Intermediate Clinical Endpoints: Improving diagnostic accuracy, speeding up diagnosis, or helping pick the right treatment are also good. These are even more powerful when the company can draw a straight line from these improvements to the hard endpoints above.
• Economic Outcomes: The platform has to lead to quantifiable cost savings. You want to see specific numbers on fewer invasive procedures, shorter hospital stays, or lower drug costs for health systems, payers, or patients. 3. Regulatory Alignment & Reimbursement Pathway:
• FDA Clearances (510(k), De Novo, Breakthrough Designation): A 510(k) is just table stakes (it means you’re like something else already on the market), whereas a De Novo clearance is a much stronger signal of real novelty. Breakthrough Device Designation is also a great sign because it speeds things up. A key diligence question: does the company have a Predetermined Change Control Plan (PCCP)? If their AI model learns and adapts, a PCCP means they won’t have to go back to the FDA for a new submission every time the model updates, which is a huge operational drag.
• CPT Codes (Category I & III): Having dedicated CPT codes, especially a Category I code, means you have a clear path to getting paid. A company that is actively working on and getting these codes shows they know how the business of American medicine actually works.
• GMLP & QMS: You have to see compliance with Good Machine Learning Practice (GMLP) and a real Quality Management System (QMS) like ISO 13485. This is basic blocking and tackling for regulatory compliance and it’s a non-negotiable for investor confidence. FDA guidance on GMLP. A company that nails all three of these isn’t just making cool tech. They are building a business with a real path to revenue and a high exit multiple. A slick feature might get you in the door, but it’s the clinical proof that builds the fortress.
  

  Methodology and Source Note

  These insights come from analyzing the published clinical trials and regulatory filings for AI in cardiology. The breakdown of Cleerly and HeartFlow is based on their papers in major cardiology journals and how well they line up with guidelines from groups like the American College of Cardiology. Everything here is grounded in public, verified data, the cost-saving numbers and clinical results are taken directly from those sources. The goal is to give investors a practical framework for spotting the AI-native health companies that are actually winning by building their moat out of clinical outcomes. While the cardiovascular AI field is moving fast, the things that create real value don’t change. For an investor, the ability to tell the difference between real clinical impact and just a cool new piece of tech will be what separates you from the pack when picking the next big AI health platform.